Loading
A phase 2 trial of Standard surgery in pancreatic ductal adenocarcinoma, run by CEBIOTEX, now recruiting.
CEB-01 in Locally Resectable Pancreatic Cancer is a phase 2 interventional study registered as NCT06538857 by CEBIOTEX, with 39 participants planned, started 2024-08-20 and due to reach its primary completion in 2028-09. Interventions recorded: Standard surgery and CEB-01.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares CEBIOTEX and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/